Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism

Overview publication

TitleGlobal, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism
DateMarch 31st, 2026
Issue nameMed
Issue numberv6.6 p100611
DOI10.1016/j.medj.2025.100611
AuthorsDemirbilek H, Melikyan M, Iotova V, Galcheva S, Ozbek MN, Dastamani A, Kheladze N, Mazor-Aronovitch K, Clemente M, Empting S, Mohnike K, Christesen HT, Thornton PS, De Leon DD, Hood D, O’Boyle E & Roberts BK
MTGsMTG7
Read Read publication